Regeneron Pharmaceuticals Inc. has published the transcript of its third-quarter 2025 earnings conference call. The event featured remarks from several key members of management, including the Co-Chairman of the Board, President, Chief Executive Officer, and Co-Founder, as well as the Co-Chairman of the Board, President, Chief Scientific Officer, and Co-Founder, the Executive Vice President of Commercial, and the Executive Vice President and Chief Financial Officer. During the call, management addressed Regeneron's latest financial results, development programs, anticipated milestones, and business outlook. The team also discussed collaborations, regulatory matters, and payer coverage for Regeneron's products. "Remarks made on today's call may include forward-looking statements about Regeneron," stated the management, emphasizing that such statements are based on current expectations and involve risks and uncertainties. The call concluded with a Q&A session, and the Investor Relations team invited further questions from interested parties. The full transcript can be accessed through the link below.